Canada markets close in 6 hours

Marvell Technology, Inc. (MRVL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
41.67-0.61 (-1.44%)
As of 10:00AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close42.28
Bid41.24 x 1000
Ask41.26 x 900
Day's Range41.06 - 41.80
52 Week Range33.75 - 76.59
Avg. Volume12,062,601
Market Cap35.553B
Beta (5Y Monthly)1.47
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.24 (0.53%)
Ex-Dividend DateJan 05, 2023
1y Target EstN/A
  • GlobeNewswire

    Syntiant Corp. Strengthens Board of Directors with Appointment of Edward Frank

    Visionary and Tech Entrepreneur Brings 35 Years of Experience to the Edge AI Chipmaker, Leading Industry Giants and Emerging Companies Syntiant Corp. Visionary and Tech Entrepreneur Edward Frank, Ph.D., Appointed to Syntiant Corp.'s Board of Directors IRVINE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Syntiant Corp., a provider of deep learning solutions for always-on edge AI applications, today announced the addition of Edward Frank, Ph.D., to its board of directors. Dr. Frank joins Syntiant’s b

  • CNW Group

    Marvell Expands Operations in Canada

    Marvell (NASDAQ: MRVL) today announced a significant expansion of its Canadian presence in Ottawa, Toronto, and Vancouver with plans for ongoing growth. The company added over 120 new employees to the Marvell Canada team this year to support the continued growth and scale of its global operations. Canada is a market of growing strategic importance for Marvell as the company continues to advance its leadership in cloud-optimized silicon.

  • Newsfile

    Marvel Biosciences Initiates Formulation Development with Catalent

    Calgary, Alberta--(Newsfile Corp. - April 6, 2022) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that has initiated its pre-clinical oral formulation studies for its lead compound MB-204 with Catalent, Inc.Catalent, one of the world's largest contract research organizations, has begun development of novel solid ...